Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
PDA Journal of Pharmaceutical Science and Technology
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

PDA Journal of Pharmaceutical Science and Technology

Advanced Search

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • Follow pda on Twitter
  • Visit PDA on LinkedIn
  • Visit pda on Facebook
EditorialGuest Editorial

PDA Responds to the Novel Coronavirus Situation

Richard M. Johnson
PDA Journal of Pharmaceutical Science and Technology March 2020, 74 (2) 170; DOI: https://doi.org/10.5731/pdajpst.2019.001118
Richard M. Johnson
President and CEO, Parenteral Drug Association Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: johnson@pda.org
  • Article
  • References
  • Info & Metrics
  • PDF
Loading

Like me, you have probably been monitoring the developing novel coronavirus situation. We are all worried about the impact to our families and our communities. We are especially concerned about those whose health has been impacted, and all whose daily routines are being disrupted. Every day, we are busy checking the latest updates, so that we can assure we are taking appropriate steps to safeguard the health and safety of our global members and staff.

Our community has a unique challenge; while we are protecting ourselves and our community, many of you have the responsibility to continue to provide critically needed healthcare products. On behalf of PDA, we want to thank you for your efforts!

Some of the actions that PDA and our partners are taking include:

  • Close and regular monitoring of the situation, adherence to recommendations from global regulatory bodies and official travel warnings.

  • Rescheduling the 2020 PDA Annual Meeting to July 20–22 at the same venues. The subsequent 2020 PDA Pharmaceutical Manufacturing Data Science Workshop will be held July 23. Annual Meeting training courses will now be held July 23–24. All existing registrations will be transferred to the new dates without penalty.

  • Rescheduling training courses scheduled for April at the PDA Training and Research Institute (TRI) in Bethesda, Md.

  • Working with INTERPHEX to postpone the event (dates to be announced).

  • Expanding options for virtual attendance at upcoming meetings as an alternative to in-person attendance.

  • Accelerating the development of online and virtual training for our community.

  • Implementing a pandemic preparedness plan for our global staff, including expanding our Work from Home program, and assuring accurate and timely information according to CDC and WHO recommendations.

Regarding other upcoming PDA events in the United States and Europe, we will continue to monitor the situation and make additional announcements as the conditions require. If you have any questions, please contact us.

I also encourage our members to follow updates and announcements from their countries' public health agencies. WHO, EMA and the U.S. CDC, among others, are sources of additional information. A series of links are posted on the PDA website.

Please continue to check the PDA website, PDA Connector email, news uPDAte and PDA Letter for further information about the impact of COVID-19 on PDA activities.

  • © PDA, Inc. 2020
PreviousNext
Back to top

In This Issue

PDA Journal of Pharmaceutical Science and Technology: 74 (2)
PDA Journal of Pharmaceutical Science and Technology
Vol. 74, Issue 2
March/April 2020
  • Table of Contents
  • Index by Author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
PDA Responds to the Novel Coronavirus Situation
(Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology
(Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 12 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
PDA Responds to the Novel Coronavirus Situation
Richard M. Johnson
PDA Journal of Pharmaceutical Science and Technology Mar 2020, 74 (2) 170; DOI: 10.5731/pdajpst.2019.001118

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
PDA Responds to the Novel Coronavirus Situation
Richard M. Johnson
PDA Journal of Pharmaceutical Science and Technology Mar 2020, 74 (2) 170; DOI: 10.5731/pdajpst.2019.001118
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Assessment of Extractable and Leachable Substances from Pharmaceutical Contact Materials: Where Are We and Where Do We Go from Here?
  • Lessons from a Pandemic: Maintaining Compliant GxP Surveillance Programs and Stable Pharmaceutical Supply
  • Scientific Studies and Interpretation
Show more Guest Editorial

Similar Articles

Readers

  • About
  • Table of Content Alerts/Other Alerts
  • Subscriptions
  • Terms of Use
  • Contact Editors

Author/Reviewer Information

  • Author Resources
  • Submit Manuscript
  • Reviewers
  • Contact Editors

Parenteral Drug Association, Inc.

  • About
  • Advertising/Sponsorships
  • Events
  • PDA Bookstore
  • Press Releases

© 2021 PDA Journal of Pharmaceutical Science and Technology ISSN: 1079-7440

Powered by HighWire